Jove
Visualize
Contact Us

Related Experiment Videos

Acute hepatitis after riluzole administration.

A J Remy1, W Camu, J Ramos

  • 1Service d'Hépato-Gastroentérologie, Hôpital Saint-Eloi, Montpellier, France.

Journal of Hepatology
|April 6, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

COVID-19 and chronic liver disease: results from the 1219 patients French registry.

Scientific reports·2025
Same author

The negative impact of HBV/HCV coinfection on cirrhosis and its consequences.

Alimentary pharmacology & therapeutics·2017
Same author

MACVIA-LR (Fighting Chronic Diseases for Active and Healthy Ageing in Languedoc-Roussillon): A Success Story of the European Innovation Partnership on Active and Healthy Ageing.

The Journal of frailty & aging·2016
Same author

The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients.

Journal of viral hepatitis·2015
Same author

Tacrolimus and the risk of solid cancers after liver transplant: a dose effect relationship.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2015
Same author

Epidemiological and prognostic factors involved in upper gastrointestinal bleeding: results of a French prospective multicenter study.

Endoscopy·2012
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Riluzole, the first treatment for amyotrophic lateral sclerosis, may cause acute hepatitis. Monitoring liver enzymes is crucial during riluzole therapy due to potential liver damage.

Area of Science:

  • Hepatology
  • Neurology
  • Pharmacology

Background:

  • Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease.
  • Riluzole is the first FDA-approved medication shown to extend survival in ALS patients.
  • The drug's mechanism involves inhibiting glutamate release and blocking postsynaptic glutamate receptors.

Observation:

  • Two patients developed acute hepatitis after taking riluzole (100 mg daily).
  • Hepatitis onset occurred after 7 and 4 weeks of treatment.
  • Liver histology revealed hepatocellular damage, inflammatory infiltration, and microvesicular steatosis without fibrosis.

Findings:

  • Riluzole administration was linked to acute hepatitis in both cases.
  • Liver enzyme levels normalized within 4-8 weeks post-discontinuation.

Related Experiment Videos

  • Re-administration of riluzole in one patient resulted in recurrent hepatitis, confirming a causal relationship.

    • Implications:

    • Riluzole can induce acute hepatitis, characterized by hepatocellular damage and microvesicular steatosis.
    • Regular monitoring of liver enzymes is recommended for patients undergoing riluzole treatment.
    • These findings highlight the importance of pharmacovigilance for novel ALS therapies.